氨磷汀联合术后FOLFIRI方案治疗中晚期直肠癌临床分析

Efficacy observation of amifostine combined with FOLFIRI regimen for patients with advanced rectum carcinoma

目的观察氨磷汀联合FOLFIRI方案治疗直肠癌根治术后患者的疗效及安全性。方法 80例直肠癌根治术后患者分为单纯化疗组(n=40)和氨磷汀联合组(n=40)。单纯化疗组给予FOLFIRI方案(伊立替康+5-氟尿嘧啶+亚叶酸钙),每2周为1周期。氨磷汀联合组在给予FOLFIRI方案基础上化疗前30 min应用氨磷汀500 mg静滴,15 min滴完。连续4个周期。评价患者的生活质量和毒副反应。结果治疗后氨磷汀联合组患者的KPS评分为(72.2±10.6),显著高于单纯化疗组的(60.4±8.5),差异有显著性(P<0.05);氨磷汀联合组感觉神经毒性和恶心呕吐发生率显著低于单纯化疗组(P<0.05)。结论氨磷汀联合FOLFIRI方案治疗直肠癌根治术后患者的疗效优于单纯FOLFIRI方案,毒副反应轻。

[ Objective ] To evaluate the efficacy and safety of amifostine combined with FOLFIRI regimen for treatment of patients with advanced carcinoma of rectum. [Methods] 80 patients after radical resection of rectal carcinoma were randomly divided into two groups. FOLFIRI chemotherapy regimen was used in simple chemotherapy group and amifostine combined chemotherapy group underwent amifostine before the start of chemotherapy （amifostine 500 mg ivgtt 15 rain） for 4 cycles combined with FOLFIRI. The quality of life and toxicity were evaluated. [Results] After two-month treatment, KPS score of amifostine-combined chemotherapy group was （72.2±10.6）, which was significantly higher than that of simple chemotherapy group （P 〈0.05）. Compared with simple chemotherapy group, toxic reactions such as sensory neurotoxicity, nanpathia and vomiting were decreased in amifostine-combined chemotherapy group （P 〈0.05）. [ Conclusion] Amifostine combined with FOLFIRI regimen is effective for patients with advanced carcinoma of rectum and it can improve quality of life.